NCT02085460View on ClinicalTrials.gov

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Head and Neck Cancer
Interventions
DRUG

Placebo

DRUG

2% Rebamipide liquid

DRUG

4% Rebamipide liquid

Trial Locations (5)

Unknown

Chubu Region

Chugoku Region

Kanto Region

Kinki Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02085460 - A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter